Janssen Pharmaceutica Nv

Renee L DesJarlais

Dennis J Hlasta

Carl R Illig

Mark James Wall

Sanath K Meegalla

Mark R Player

Jinsheng Chen

Hui Huang

Michael H Parker

Carl L Manthey

Carsten Schubert

Christopher J Molloy

Christopher M Flores

Bart L DeCorte

Shelley K Ballentine

Edward Charles Lawson

Kenneth Jerome Wilson

Yifang Huang

Kimberly White

Kenneth J Wilson

Shyamali Ghosh

M Jonathan Rudolph

Alfonzo D Jordan

Daniel A Hutta

Jonathan Rudolph

Hu Huaping

Shelley K Balltentine

Kimberly B White

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Method of inhibiting C-KIT kinase

The present invention is directed to 4,4-di-substituted piperidine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)

The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Bicyclic derivatives useful as inhibitors of DPP-1

The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, n, Z, and Rare described in the specification.

5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, Rand W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

Class of arylamide compounds useful as inhibitors of c-fms kinase

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, Rand Rare described in the specification.

5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase

Growing community of inventors

Saint Davids, PA, United States of America

Renee L DesJarlais